MINNEAPOLIS, Minnesota — Entellus Medical, which is developing a less-invasive therapy for chronic sinusitis, has closed a $30-million round of funding.
The three-year-old company will use the funding to expand its sales and customer support teams, and prepare to launch its sinus-treatment system in Europe.
Entellus has raised $57 million to date, Finance and Commerce reported.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company’s latest round of financing was led by new investor Essex Woodlands Health Ventures and supported by existing investors Split Rock Partners and SV Life Sciences, according to the statement.
Entellus’ FinESS sinus treatment is designed to relieve the need for antibiotics or invasive surgery to treat chronic sinusitis, a condition in which the cavities around the nasal passage become inflamed and swollen, interfering with nasal drainage. The company says its treatment reduces a patient’s recovery time, because it doesn’t require removing bone or sinus tissue.
A key challenge for the company will be convincing insurers to cover its sinus treatment in an office setting, Finance and Commerce reported. The therapy is currently available at hospitals and medical offices.
